Becton Dickinson and Company (BDX)vsBionano Genomics Inc (BNGO)
BDX
Becton Dickinson and Company
$158.27
+1.51%
HEALTHCARE · Cap: $56.49B
BNGO
Bionano Genomics Inc
$1.20
+1.69%
HEALTHCARE · Cap: $11.13M
Smart Verdict
WallStSmart Research — data-driven comparison
Becton Dickinson and Company generates 76237% more annual revenue ($21.92B vs $28.72M). BDX leads profitability with a 8.0% profit margin vs -134.4%. BDX earns a higher WallStSmart Score of 61/100 (C+).
BDX
Buy61
out of 100
Grade: C+
BNGO
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+36.9%
Fair Value
$286.42
Current Price
$158.27
$128.15 discount
Intrinsic value data unavailable for BNGO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Earnings expanding 28.6% YoY
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 21.3% year-over-year
Areas to Watch
Moderate valuation
1.6% revenue growth
ROE of 7.0% — below average capital efficiency
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -78.2% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : BDX
The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.16 suggests the stock is reasonably priced for its growth.
Bull Case : BNGO
The strongest argument for BNGO centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 21.3% demonstrates continued momentum.
Bear Case : BDX
The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : BNGO
The primary concerns for BNGO are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
BDX profiles as a value stock while BNGO is a growth play — different risk/reward profiles.
BNGO carries more volatility with a beta of 1.72 — expect wider price swings.
BNGO is growing revenue faster at 21.3% — sustainability is the question.
BDX generates stronger free cash flow (549M), providing more financial flexibility.
Bottom Line
BDX scores higher overall (61/100 vs 39/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Becton Dickinson and Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Visit Website →Bionano Genomics Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Bionano Genomics, Inc. is a life science instrumentation company in the genome analysis space. The company is headquartered in San Diego, California.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?